
    
      -  To determine the maximum tolerated dose (MTD) and a recommended phase II dose (RP2D) of
           Velcade® when administered as a twice weekly 3-5 second IV bolus every 3 weeks to
           patients with malignancies of the brain, head and neck and cervix who receive 2-8 weeks
           of chemoradiation.

        -  To evaluate the safety and toxicity profile of Velcade® when administered on a twice
           weekly (days 1, 4, 8 and 11) every 3 weeks (maximum 8 weeks) concurrent with
           chemoradiation.

        -  To evaluate tumor response
    
  